bioAffinity Technologies, Inc. 8-K

What Happened

• bioAffinity Technologies, Inc. filed a Form 8-K on June 30, 2026 to announce the release of its Company Newsletter (Exhibit 99.1), 1st Edition, 2nd Quarter 2026. The newsletter provides an overview of recent corporate developments and includes forward-looking statements about the company’s plans and expectations.
• The filing highlights forward-looking language and cautions investors that actual results may differ due to risks and uncertainties, including the company’s ability to successfully commercialize CyPath® Lung and regulatory risks related to laboratory developed tests. The company refers investors to its Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for additional risk factors.

Key Details

• Filing date: June 30, 2026; Newsletter attached as Exhibit 99.1 (Company Newsletter, 1st Edition, 2nd Quarter 2026).
• Newsletter contains forward-looking statements and a forward-looking statement disclaimer; company does not undertake to update these statements except as required by law.
• Specific risks called out include commercialization of CyPath® Lung and the regulatory environment for laboratory developed tests.
• The 8-K did not report financial results, executive changes, or transaction details.

Why It Matters

• For investors, the filing signals company communication about product development (CyPath® Lung) and reiterates material risks that could affect future performance. While no financial or operational metrics were disclosed in this 8-K, the newsletter and the forward-looking statements identify commercialization and regulatory outcomes as key drivers to monitor in future updates and SEC filings.